The Palm Beach Post reported that the Scripps Research Institute has started issuing home loans — I guess they heard about the sub-prime bonanza and decided to jump on the bandwagon. Despite sounding like they’ve branched into some wildly diversified operations, the loans come as a bribe an incentive to get top scientists to move […]
The U.S. Patent and Trademark Office (USPTO) came down on the side of Wisconsin Alumni Research Foundation (WARF) in upholding one of its patents on human embryonic stem cells. WARF’s licensee, Geron Corp., holds an exclusive license to these patents to develop and commercialize therapies based on three types of cells derived from human embryonic stem cells: neural […]
Robert Shapiro, chairman of Sonecon, LLC, and former advisor to U.S. President Bill Clinton and British Prime Minister Tony Blair, has published a study on the potential savings when generic biologic treatments (biogenerics) find a pathway in the U.S. I say when and not if since the government is the largest consumer of medical care […]
Drug developers often search for new leads in the biodiversity often found in developing countries. Often, a new theraputic or genetically engineered product is developed and patented. Depending upon your view, this is either the free market at play in creating new and better products (so-called bioprospecting) or exploitation of developing nations (so-called biopiracy). However, […]
A new website popped up recently that is an attempt to serve as a global resource for dialogue on intellectual property rights and its role in advancing research and innovation. The site, called Essential Innovation, is an online forum that will feature commentary and analysis on the importance of continued innovation, and the potential consequences […]
A newly formed nonprofit corporation unites industry, academia and government in first large-scale study of genetics and drug safety. The Serious Adverse Event Consortium (SAEC) will work to identify genetic markers that may help predict which individuals are at risk for serious drug-related adverse events (SAEs). Pharmacogenetics and pharmacogenomics deal with the genetic basis underlying […]
About Biotech talks about Biotech Business Models this week, such as the Platform, Product and Vertical models for early-stage biotech companies. In all cases, patents and IP rights are noted to be at the core of any venture. Noteably is that the Platform business model has persevered, combined with contract research and services for the […]
It appears, for now at least, that the legislation creating an approval pathway for follow-on biologics will not be included in the FDA Revitalization Act (FDARA). FDARA would reauthorize the Prescription Drug User Fee Act or PDUFA (pronounced puh-doo-fuh), which expires Sept. 30. PDUFA increases funding for the Food and Drug Administration through fees paid […]
Served Up Daily
Editor-in-Chief Barista Stephen Jenei is a patent attorney and Owner of Jenei LLC. When not serving up patent chat over a steaming cup of java, he's handling a diverse intellectual property practice in the biotechnology, pharmaceutical and chemical fields. More info @ Jenei LLC
